Columbia Lab-to-Market Programs
CONTENTS

About L2M
Partnering with L2M
L2M at a Glance

Active Programs

1. Accelerating Cancer Therapeutics (ACT)
2. Biomedical Engineering Technology Accelerator (BiomedX)
3. Translational Therapeutics Accelerator (TRx)
4. New York State Biodefense Commercialization Fund
5. Carbontech Development Initiative (CDI)
6. Center for Smartscape (CS3)
7. Columbia-NYU-Takeda Alliance
8. Columbia-Deerfield: Hudson Heights Innovations

Dormant Programs

1. Cyber NYC Inventors to Founders (I2F)
2. 'Math Meets Bio' Columbia - AlleyCorp Collaboration
3. NYC Media Lab Combine
4. PowerBridgeNY
5. RTW Charitable Foundation Accelerator
6. Columbia-IBM Launch Accelerator
7. Columbia-SDP Oncology Research Alliance
8. Columbia-Corning Advanced Materials Prize
The Columbia Lab-to-Market (L2M) Accelerator Network serves as a framework to successfully develop, launch, and execute initiatives to help commercialize academic research. Since 2008, Columbia University has founded or co-founded multiple accelerator programs encompassing medical technologies, clean energy technologies, therapeutics, and digital media, providing resources to foster the development of concepts and companies that have subsequently raised more than $285M in additional funding.
PARTNERING WITH L2M

Lab-to-Market programs are made possible by the incredible support of our diverse pool of partners, sponsors, and mentors.

WHAT MAKES A GOOD PARTNER?
• Provides mentorship to founders as leaders, domain expertise and general business guidance to validate, fund, and launch early ventures.
• Makes time for fireside chats and guest speaker engagements.
• Supports community and network building.
• Invests in accelerator teams.

WHY PARTNER?
• Maximize your impact through L2M’s efficient approach to building programs and sharing resources.
• Grow your reach across campuses and institutions through L2M’s robust programming while staying connected to cutting edge research.
• Collaborate, network, and engage in a forum where information and lessons are shared.

Join the Network Today
Partner Intake Form
## L2M Network at a Glance

<table>
<thead>
<tr>
<th>Program</th>
<th>Funding</th>
<th>Focus Areas</th>
<th>Target Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accelerating Cancer Therapeutics (ACT)</td>
<td>Mix (NIH, CU)</td>
<td>Cancer-related Therapeutics</td>
<td>CU Faculty</td>
</tr>
<tr>
<td>Biomedical Engineering Technology Accelerator (BioMedX)</td>
<td>Mix (Philanthropic, CU)</td>
<td>Biomedical Engineering</td>
<td>CU Faculty</td>
</tr>
<tr>
<td>Carbontech Development Initiative (CDI)</td>
<td>Public (NYSERDA)</td>
<td>Carbon Capture</td>
<td>New York State</td>
</tr>
<tr>
<td>Center for Smart Streetscapes (CS3)</td>
<td>Public (NSF ERC)</td>
<td>Smart Cities</td>
<td>National</td>
</tr>
<tr>
<td>Corning Advanced Materials Prize</td>
<td>Private (Corning)</td>
<td>Advanced Materials</td>
<td>CU Faculty</td>
</tr>
<tr>
<td>CU - RTW Rare Diseases Alliance</td>
<td>Private (RTWCF)</td>
<td>Rare Diseases</td>
<td>New York City</td>
</tr>
<tr>
<td>CU - IBM Launch Accelerator</td>
<td>Private (IBM)</td>
<td>Deep Tech</td>
<td>New York City</td>
</tr>
<tr>
<td>CU - NYU - Takeda Alliance</td>
<td>Private (Takeda)</td>
<td>Gastroenterology</td>
<td>CU / NYU Faculty</td>
</tr>
<tr>
<td>CU - SDP Oncology Research Alliance</td>
<td>Private (Sumitomo)</td>
<td>Oncology</td>
<td>CU Faculty</td>
</tr>
<tr>
<td>Cyber NYC (i2F)</td>
<td>Public (NYCEDC)</td>
<td>Cybersecurity</td>
<td>New York City</td>
</tr>
<tr>
<td>Hudson Heights Innovation</td>
<td>Private (Deerfield)</td>
<td>Therapeutics</td>
<td>CU Faculty</td>
</tr>
<tr>
<td>'Math Meets Bio' CU - AlleyCorp Collaboration</td>
<td>Private (AlleyCorp)</td>
<td>Computational Biology</td>
<td>New York City</td>
</tr>
<tr>
<td>NYC Media Lab Combine</td>
<td>Public (NYCEDC)</td>
<td>Emerging media tech</td>
<td>New York City</td>
</tr>
<tr>
<td>NYS Biodefense Commercialization Fund</td>
<td>Public (NYS ESD)</td>
<td>Pandemic Preparedness</td>
<td>New York State</td>
</tr>
<tr>
<td>PowerBridgeNY</td>
<td>Public (NYSERDA)</td>
<td>Clean Tech</td>
<td>New York State</td>
</tr>
<tr>
<td>Translational Therapeutics Accelerator (TRx)</td>
<td>Mix (NIH, CU)</td>
<td>Therapeutics</td>
<td>CU Faculty</td>
</tr>
</tbody>
</table>

- **567 Alumni Teams**
- **302 Cash Awards**
- **$42.2M Awarded to Teams**
- **$285.1M Follow-on Funding**
- **90+ Commercial Launches**
ACTIVE PROGRAMS
Accelerating Cancer Therapeutics (ACT) is an accelerator program designed to leverage Columbia’s proficiency in drug discovery and provide access to entrepreneurs and the pharmaceutical industry to advance novel cancer therapeutics from the lab towards the path of commercialization and clinical implementation. The program provides education, mentorship and funding to help academic translational research projects move beyond the “valley of death” in therapeutic development and reach significant milestones.

Areas of Focus

- All cancer-related therapeutics projects
- Principal Investigators or teams of investigators from underrepresented groups
- Therapeutic strategies including small molecules, biologics, novel delivery approaches, gene therapy, and cell therapeutics
The BiomedX program aims to catalyze the advancement of Columbia biomedical technologies. The program provides funding, education, resources, and mentorship to teams of clinicians, engineers, and scientists to develop solutions for unmet clinical needs, with the ultimate goal of bringing innovative research out of the lab to benefit society. Participating teams will be eligible to submit a full proposal application for a one-year grant of up to $100,000 per project.

Areas of Focus
- Technologies that directly impact human health (medical devices, diagnostics, software, platform technologies, etc.)
- Translation to market within 3–5 years
- Remote medicine, patient experience, care coordination, leakage reduction, and provider efficiency and wellness

Columbia | BiomedX
Biomedical Engineering Technology Accelerator
The TRx program is a therapeutic development accelerator aimed at translating the outstanding discoveries at Columbia University into commercial therapeutics. Investigators in all therapeutic areas are encouraged to apply. Of interest are novel therapeutic targets or innovative ideas that have a clear path towards commercialization. Funding from this pilot award is intended to move projects forward to a value inflection point so that they are eligible to explore later stage funding opportunities through Government or Foundation grants and/or industry partnerships.

**Areas of Focus**
- Rare diseases originating from precision medicine
- Pain and addiction (e.g., management & treatment)
- Unmet needs for diseases and public health concerns that disproportionately affect underserved communities
- Applications from Principal Investigators or teams of investigators from underrepresented groups

**Funding: Mixed (NIH, CU)**

2016 – Present

**TRANSLATIONAL THERAPEUTICS ACCELERATOR**

- **84 Teams**
- **37 Awards**
- **$1.4M Total Funding**

**Areas of Focus**
- Rare diseases originating from precision medicine
- Pain and addiction (e.g., management & treatment)
- Unmet needs for diseases and public health concerns that disproportionately affect underserved communities
- Applications from Principal Investigators or teams of investigators from underrepresented groups

**COLUMBIA | TRx**

**IRVING INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH**

**LINK TO INTEREST FORM**
**LINK TO PROGRAM HOMEPAGE**
NEW YORK STATE BIODEFENSE COMMERCIALIZATION FUND

The $40 million Biodefense Commercialization Fund aims to promote and expedite the development and commercialization of solutions for major infectious diseases, including COVID-19 and its variants. It supports the formation and growth of life science businesses. The Fund provides grants to startups and academic centers working on promising innovations in diagnostics, vaccines, therapeutics, pathogen surveillance tools to address infectious disease threats.

Areas of Focus

- Therapeutic, diagnostic, digital epidemiology, and pathogen surveillance & containment
- Small molecule therapeutics
- Novel platform diagnostics targeting COVID variants and other infectious diseases

Funding: State (ESD)

2021 – Present

87 Teams

24 Awards

23.7M Non-Dilutive Funding
The Carbontech Development Initiative (CDI) is a large-scale market transformation grant-seeding and commercialization initiative for carbontech science and technology. CDI aims to position New York State as a global carbontech hub by supporting research and development, facilitating technology transfer, and commercializing innovation. By leveraging the deep bench of technical expertise at Columbia University and the entrepreneurial dynamism of New York State, CDI will promote the decarbonization solutions required to address the climate crisis and catalyze economic development.

**Areas of Focus**
- CO2 Capture Technology
- CO2-to-Building Materials
- CO2-to-Chemicals, Fuels, & Materials
Led by Columbia in partnership with Florida Atlantic University, Rutgers University, University of Central Florida, and Lehman College, the Center for Smart Streetscapes (CS3) is the only federally funded large-scale research center focusing on smart city technologies and will focus on forging livable, safe, and inclusive communities through real-time, hyper-local streetscape applications built on advancements in edge-cloud technology, wireless-optical engineering, visual analytics, computer security, and social science.

**Areas of Focus**
- Road Safety & Efficiency
- Public Safety
- Assistive Technologies
- Future of Outdoor Work
- Hyper-Local Environmental Sensing

**Technology Focus Areas**
- 5

**Program Funding**
- $26M

**Test Bed Sites**
- 3
Columbia University, New York University, and Takeda Pharmaceuticals have partnered to propel gastroenterology research and the development of new treatments for GI disorders. Leveraging Takeda’s R&D capabilities and funding, the alliance aims to bridge the gap between the universities' early-stage technologies and commercialization. The collaboration will further innovative, high-risk concepts aligned with Takeda’s GI Drug Discovery Unit’s strategies. Sponsored research will be advanced institutionally, with award decisions made by a joint committee from Columbia, NYU, and Takeda.

**Areas of Focus**
- Gut inflammation
- Liver disease
- Motility disorders
- Translational and clinical
- Cell and gene therapy
- Drug delivery

**COLUMBIA–NYU–TAKEDA ALLIANCE**

2 Cycles Completed  
13 Awards  
$1.17M Total Funding

Funding: Corporate (Takeda)  
2019 - Present
Hudson Heights Innovations is a partnership between Columbia University and Deerfield Management aimed at transforming biomedical discoveries into novel treatments for enhanced quality of life and disease cures. Launched on June 5th, 2019, this collaboration was backed by an initial funding of up to $130 million over 10 years from Deerfield and its partners. In addition to funding, Deerfield lends development expertise to support innovative drug research.

Areas of Focus

- Hard-to-treat and rare diseases
- High-need therapeutics
- Improving quality of life and treatment
DORMANT PROGRAMS
Launched in 2019, Cyber NYC was a $100M public-private partnership driven by the New York City Economic Development Corporation (NYCEDC) to energize the cyber startup ecosystem. The Inventors to Founders (I2F) initiative was specifically aimed at fostering cybersecurity and data privacy startups from premier academic institutions. I2F served as an early-stage accelerator and talent network, providing tailored programs and financing to expedite the commercialization of innovative cybersecurity research from academia.

Components of the I2F Initiative

- “Pre-seed” Startup Accelerator
  - Connected startups with capital, talent, and networks
- Talent Matching Platform
  - Connected university technologists with operators

9 Universities  
8 Accelerator Graduates  
$750K Total Funding
The 'Math Meets Bio' collaboration between Columbia and AlleyCorp aimed to expedite the market transition of innovative technologies and boost startup activity at the intersection of mathematics and biology in the New York Life Science-Tech ecosystem. The strategic research alliance was a collaboration with New York based venture firm AlleyCorp to support new innovation in life sciences powered by computational biology.

**COLUMBIA–ALLEYCORP: 'MATH MEETS BIO'

- **8 Teams**
- **3 Awards**
- **$286K Total Funding**

Funding: VC (Alleycorp)

2021 - 2022
NYC Media Lab’s Combine was a lean startup accelerator that promoted entrepreneurship in emerging media technology for university startups, corporate intrapreneurship programs, and executive education. It aimed to facilitate entrepreneurs and innovative companies to leverage NYC Media Lab’s community and the city’s robust technology ecosystem. The accelerator paired faculty and students developing new technologies with a lean process for customer discovery and business model generation.

**Areas of Interest**
- Emerging media technologies
- Artificial Intelligence
- Machine Learning
- Computer Vision
- Natural Language Processing
- Virtual & Augmented Reality
- Voice, Audio, and/or Neural Interfaces

**NYC Media Lab Combine**

- **48 Teams**
- **45 Awards**
- **$9.4M Total Funding**

**2015 – 2020**

**Funding: Municipal (NYCEDC)**

// LINK TO PROGRAM HOMEPAGE
PowerBridgeNY was an accelerator program established in 2013 to expedite the commercialization of cleantech for scientists and entrepreneurs. It supported technologists in determining product-market fit, de-risking their technologies through prototype development, and validating their technology via customer and industry engagement. The program offered $150K for teams to conduct customer discovery interviews and develop prototypes or perform in-field testing, in addition to providing workshops, mentorship, and access to expertise in various fields using the NSF I-Corps/Lean LaunchPad Methodology.

81 Teams

51 Awards

$46M Total Funding

Funding: State (NYSERDA)

2013 – 2019

// LINK TO PROGRAM HOMEPAGE
Administered by Columbia Technology Ventures, the accelerator was a strategic research alliance with the RTW Charitable Foundation and select New York-based academic institutions, aiming to accelerate translational research in ultra-rare and underfunded diseases. The RTW Charitable Foundation, created at the convergence of scientific advancements and humanitarian efforts, provides funding, leadership, and scientific expertise to support pioneers battling diseases that might lack commercial appeal but result in significant human suffering.

**Areas of Focus**
- Central Nervous System
- Cardiovascular
- Immunology/Autoimmune Diseases

**2021 – 2022**

**RTW CHARITABLE FOUNDATION ACCELERATOR**

Funding: Foundation (RTWCF)

- **8 Teams**
- **3 Awards**
- **$375K Total Funding**

// LINK TO PROGRAM HOMEPAGE
The Columbia-IBM Launch Accelerator was a non-dilutive program for building and scaling successful early-stage companies in big data and deep tech. The goal of the program was to help the best emerging ventures succeed through education, mentorship, and business model design. The program was a pillar of the Columbia IBM Center for Blockchain and Data Transparency.

Areas of Focus
- Blockchain
- Data Transparency
- Artificial Intelligence
- Machine Learning
- Natural Language Processing
- Cybersecurity
- Deep Tech

27 Teams
27 Awards
$273K Non-Dilutive Funding

The Columbia | IBM Launch Accelerator
Columbia University and Sumitomo Dainippon Pharma Oncology (SDP Oncology) formed the Columbia–SDP Oncology Research Alliance. This collaboration aimed to accelerate research and development in oncology via projects initiated by Columbia investigators. The alliance funded translational research by three researchers from the Herbert Irving Comprehensive Cancer Center (HICCC). Winning proposals investigated novel cancer therapeutics with the potential to significantly influence cancer research.

Learn about the winning teams here.
The Columbia–Corning Advanced Materials Prize supported interdisciplinary Columbia-based teams developing innovative advanced materials technologies with the potential to transform industries. Accepted semi-finalist teams had access to top business and technical experts from Corning and the broader entrepreneurial community. Teams received funding for lab work as well as access to Corning materials, equipment, mentorship, and advice.

Areas of Focus
- Materials, equipment and systems for life sciences
- Ceramic materials
- Materials for quantum computing
- To learn more about the prize’s areas of focus, click here.
- Advanced coatings and paints
- Photonic and display technology
- Battery technologies
GET INVOLVED & STAY IN TOUCH

Newsletter
To stay up to date on program announcements, updates from cohort teams, and award funding from across the Lab-to-Market landscape, please subscribe to our newsletter.

SUBSCRIBE HERE

Sponsor, Partner, Mentor
Each Lab-to-Market program is incredibly fortunate to engage incredible sponsors, partners, and mentors from across the early-stage entrepreneurial ecosystem. If you are interested in getting involved please fill out the 5-minute intake form below.

INTAKE FORM